[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tenofovir-alafenamide-fumarate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tenofovir-alafenamide-fumarate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100504852","phase-4-study-of-tenofovir-alafenamide-in-hbv-infected-pregnant-women-100504852",false,"NCT05853718","Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women","Study to Evaluate the Pharmacokinetic, Safety, and Efficacy of TAF in HBV-Infected Pregnant Women","Inclusion Criteria:\n\n* Age of 20-40 years; Positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg); HBV DNA level \\>200 000 IU\u002FmL during the 24th-32nd week of pregnancy; Willing to take TAF for mother-to-child blockade; Both husband and wife are willingly sign an informed consent.\n\nExclusion Criteria:\n\n* Co-infected with hepatitis C or HIV, or other chronic diseases; History of spontaneous abortion or congenital malformation; Decompensated cirrhosis and liver cancer; History of kidney injury, CCr \\\u003C50ml\u002Fmin and urine protein test positive (\\>300mg\u002FL); Fetal malformations detected by B-ultrasound during pregnancy; ALT \\> 2×upper limit of normal (ULN); TBIL ≥ 1×ULN; Albumin (ALB) \\\u003C 25 g\u002FL.","FEMALE","20 Years","40 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.",[27,28],"Chronic Hepatitis b","Tenofovir Alafenamide Fumarate",[30,31,32,33,34],"pharmacokinetics","CHB","TAF","pregnancy","mother-to-child transmission","RECRUITING","2025-08-31",{"date":38,"type":39},"2025-09-08","ACTUAL",{"date":41,"type":39},"2021-05-06",{"date":43,"type":21},"2025-12-30",{"name":45,"class":46},"First People's Hospital of Hangzhou","OTHER"]